Sectoral Asset Management Inc. Grows Stake in Abbott Laboratories $ABT

Sectoral Asset Management Inc. grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 36.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,498 shares of the healthcare product maker’s stock after purchasing an additional 6,300 shares during the quarter. Abbott Laboratories comprises about 2.3% of Sectoral Asset Management Inc.’s investment portfolio, making the stock its 10th biggest position. Sectoral Asset Management Inc.’s holdings in Abbott Laboratories were worth $2,944,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Freemont Management S.A. grew its position in Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab acquired a new stake in Abbott Laboratories in the 4th quarter worth $116,580,000. Danica Pension Livsforsikringsaktieselskab acquired a new stake in Abbott Laboratories in the 3rd quarter worth $185,640,000. Thrivent Financial for Lutherans grew its position in Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the last quarter. Finally, AE Wealth Management LLC grew its position in Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after purchasing an additional 11,264 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several research analyst reports. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research report on Wednesday, April 22nd. Raymond James Financial decreased their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Leerink Partners decreased their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. UBS Group decreased their price target on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Finally, Benchmark decreased their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $119.43.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock worth $353,097 in the last 90 days. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $87.42 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm’s 50-day simple moving average is $96.74 and its 200-day simple moving average is $111.97. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The firm has a market cap of $152.27 billion, a P/E ratio of 24.49, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the business earned $1.09 EPS. The firm’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26
• Positive Sentiment: Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story
• Neutral Sentiment: One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)
• Negative Sentiment: Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
• Negative Sentiment: Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.